New Insights into Epigenetic Regulation in Cancer

A special issue of Epigenomes (ISSN 2075-4655).

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 204

Special Issue Editor


E-Mail Website
Guest Editor
Epigenetics and Disease Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia
Interests: molecular epigenetics; chromatin dynamics; regulation of gene expression; transcriptomics; hypoxic signalling; cancer metastasis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Epigenetic modifications of histones as well as DNA and RNA molecules are key regulatory mechanisms that alter gene expression. The deregulation of this process has been recognized as a key factor contributing to tumor development and progression. Epigenetic regulators can silence the expression of tumor suppressors and activate oncogenes, thereby influencing both the initiation and the progression of the disease. In addition, their ability to alter the genetic landscape in response to external stimuli represents a key factor in cellular adaptation to changes in the microenvironment. A molecular understanding of the role that epigenetic regulators play will translate into approaches that advance therapeutic strategies for cancer patients.

The present Special Issue aims to publish high-quality research articles, as well as review contributions, on a variety of topics related to epigenetic regulators and therapeutic developments.

Potential topics include, but are not limited to, the following:

  • Novel epigenetic targets in cancer.
  • Tumor microenvironment.
  • Epitranscriptomics.
  • Epigenetic editing.
  • Current state of epigenetic therapies in cancer.
  • Methods of new epigenetic therapy development.

Dr. Jason S. Lee
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Epigenomes is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer epigenetics
  • epitranscriptomics
  • epigenetic therapy

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop